Table 2.
Incidence of head and neck carcinomas arising in patients with HIV and AIDS.
| Ref # | Year | Country | # patients | # Cases | Cancer site (Subtype) | SIRs or RR (95% CI) | HIV/AIDS |
|---|---|---|---|---|---|---|---|
| [4] | 2005 | Switzerland | 7304 | 11 | 1 Lip, 4 tongue, 4 mouth, 1 pharynx, 1 NPC (?) | SIR = 4.1 (2.1–7.4) | not specified |
|
| |||||||
| [6] | 1999 | S. Europe | 5281 | 2 | SG (?) | SIR = 33.6 (3.2–123.5) | AIDS |
| 1 | NPC | SIR = 10.3 (0.0–58.8) | AIDS | ||||
|
| |||||||
| [7] | 2006 | Uganda | 12,607 | 3 | Thyroid | SIR = 5.7 (1.1–16.0) | Not specified |
| 6 | Conjunctiva (SCC) | SIR = 4.0 (1.5–8.7) | Not specified | ||||
|
| |||||||
| [15] | 1996 | USA | 50,050 | 4 | NPC (2 SCC + 2 LEC) | RR = 2.4 (0.7–6.2) | AIDS |
|
| |||||||
| [8] | 2002 | Australia | 8118 | 6 | Lip (SCC) | SIR = ~6 (~2–9.5)* | HIV |
| 8118 | 6 | Lip (SCC) | SIR = ~6.9 (~1.8–9.6)* | HIV | |||
| 7061 | 4 | Lip (SCC) | SIR = ~3.0 (0.8–8.1)* | HIV | |||
| 2112 | 3 | Lip (SCC) | SIR = ~9.0 (~3.0–>10)* | AIDS | |||
|
| |||||||
| [16] | 2004 | UK | 8640 | 7 | 2 NPC; 3 oral cavity (SCC) 2 larynx (SCC) | SIR = 1.66 (0.67–3.42) | 2 (AIDS); 5 (HIV) |
|
| |||||||
| [9] | 2000 | USA | 309,365 | 29 | Tonsil (SCC) | RR = 2.6 (1.8–3.8) | HIV/AIDS |
| 7 | Conjunctiva (SCC) | RR = 14.6 (5.8–30.0) | |||||
|
| |||||||
| [17] | 2003 | Scotland | 2574 | 1 | H&N (unspecified, not KS) | SIR = 1.6 (0.04–8.8) | Unknown |
|
| |||||||
| [10] | 2009 | USA | 499,230 | 59 | Oropharynx (SCC) | SIR = 1.6 (1.2 to 2.1) | AIDS |
|
| |||||||
| [11] | 2005 | England | 33,190 | 6 | Oral (?) | SIR = 1.1 (0.4–2.3) | HIV |
| 4 | NPC (?) | SIR = 5.0 (1.4–12.8) | HIV | ||||
| 1 | Nasal Cavity (?) | SIR = 1.7 (0.04–9.4) | HIV | ||||
| 5 | Larynx (?) | SIR = 2.0 (0.7–4.8) | HIV | ||||
| 12126 | 5 | Oral (?) | SIR = 3.8 (1.2–8.8) | AIDS | |||
| 1 | NPC (?) | SIR = 5.8 (0.1–32.5) | AIDS | ||||
| 1 | Nasal Cavity (?) | SIR = 7.9 (0.2–44.0) | AIDS | ||||
| 2 | Larynx (?) | SIR = 3.2 (0.4–11.6) | AIDS | ||||
|
| |||||||
| [12] | 2008 | USA | 491,048 | 15 | Conjunctiva (SCC) | SIR = 12.2 (6.8–20.2) | AIDS |
|
| |||||||
| [13] | 2002 | Australia | 13,067 | 10 | Lip (?) | SIR = 2.26 (1.08–4.16) | Not specified |
| 2 | Tongue (?) | SIR = 1.66 (0.20–5.99) | Not specified | ||||
| 2 | SG (?) | SIR = 3.88 (0.47–14.0) | Not specified | ||||
| 2 | Nasopharynx (?) | SIR = 2.74 (0.33–9.89) | Not specified | ||||
| 1 | Nose/sinuses/ear (?) | SIR = 2.97 (0.08–16.5) | Not specified | ||||
| 1 | Larynx (?) | SIR = 0.60 (0.02–3.34) | Not specified | ||||
| 1 | Eye (?) | SIR = 1.73 (0.04–9.64) | Not specified | ||||
| 1 | Thyroid (?) | SIR = 0.56 (0.01–3.12) | Not specified | ||||
|
| |||||||
| [14] | 2009 | USA | 519,934 | 43 | SG (All types) | SIR = 1.8 (1.3–2.4) | AIDS |
| 12 | SG (SCC) | SIR = 4.9 (2.5–8.6) | AIDS | ||||
| 7 | SG (LEC) | SIR = 39 (16–81) | AIDS | ||||
| 6 | SG (Acinar cell ca) | SIR = 1.9 (0.7–4.1) | AIDS | ||||
| 5 | SG (MEC) | SIR = 0.6 (0.2–1.5) | AIDS | ||||
| 2 | SG (Adenoid Cystic Ca) | SIR = 0.6 (0.1–2.0) | AIDS | ||||
| 2 | SG (Adenoca) | SIR = 0.7 (0.1–2.5) | AIDS | ||||
| 39 | NPC (All types) | SIR = 2.0 (1.4–2.7) | AIDS | ||||
| 22 | NPC (Ker SCC) | SIR = 2.4 (1.5–3.7) | AIDS | ||||
| 10 | NPC (NK Carc) | SIR = 2.4 (1.2–4.4) | AIDS | ||||
| 5 | NPC (LEC) | SIR = 2.1 (0.7–4.9) | AIDS | ||||
| 5 | NPC (NK SCC) | SIR = 2.8 (0.9–6.6) | AIDS | ||||
| 7 | NPC (Other/?) | SIR = 1.1 (0.5–2.3) | AIDS | ||||
Bold values indicate cancer sites where the 95% confidence interval does not include one.
SIR: standardized incidence ratio, RR: relative risk, SG: salivary gland, SCC: squamous cell carcinoma, NK: nonkeratinizing, NPC: nasopharyngeal carcinoma, H&N: head and neck, Ker: keratinizing, LEC: lymphoepithelial carcinoma, Adenoca: Adenocarcinoma.